HIGHLIGHTS

  • NGS acquires 100% of Sprout Organic for ~A$8M in scrip, creating a birth-to-teen nutrition platform.
  • Combined CY2025 Revenue of approximately USD 5.33 million; ~A$870,000 in annualised cost savings identified.
  • Sprout products already distributed through 1,000+ retail outlets including Chemist Warehouse and Woolworths Online.

 

Nutritional Growth Solutions Limited (ASX:NGS) opened the trading week with its shares rising 5% to A$0.021 after the company announced a binding Share Sale Agreement to acquire 100% of Sprout Organic Pty Ltd. The transaction, structured entirely as a scrip deal, will see NGS issue approximately 401.2 million new shares at a deemed price of A$0.02 per share, implying an upfront consideration of roughly A$8.0 million for the target. The announcement represents a strategic turning point for the Melbourne-based nutrition company, which has historically focused on its Healthy Heights clinically backed growth products for older children.

Sprout Organic is the developer and owner of the world's first product to receive regulatory approval from Food Standards Australia New Zealand (FSANZ) as a 100% organic, plant-based infant formula. This distinction is commercially significant: FSANZ approval for infant formula is notoriously difficult to obtain and represents a substantial regulatory moat that effectively limits direct competition in the category. The product is free from dairy, soy, and common allergens, and is underpinned by proprietary formulation intellectual property and provisional patents.

The Market Problem Sprout Was Built to Solve

Australia occupies a unique epidemiological position in the global infant nutrition market. The country is frequently cited on a per-capita basis as one of the world's leaders in childhood food allergies, with up to 10% of Australian infants affected by some form of allergy and more than 2% diagnosed with cow's-milk protein allergy. For these families, conventional dairy- and soy-based infant formulas are not a viable feeding option, creating a structural and effectively non-discretionary Demand for allergen-friendly alternatives. At the same time, changing consumer preferences are amplifying this demand. Approximately 72% of Millennials — the cohort now raising young children — report a strong interest in plant-based foods, suggesting that the addressable market for Sprout's products extends well beyond the allergy-sensitive population.

NGS argues that this convergence of medical necessity and lifestyle preference creates a durable, structurally underpinned demand driver rather than a passing consumer trend. With no direct global equivalent holding FSANZ approval, Sprout currently occupies an uncontested position in this niche, a characteristic that management expects to persist as a Competitive Advantage during any near-term expansion phase.

Strategic Rationale: Building a Birth-to-Teen Brand

The commercial logic of the combination rests on a lifecycle coverage argument that both management teams find compelling. Parents of infants face a recurring challenge: trusted nutrition brands typically cover only a narrow age window, forcing families to change products — and restart the anxiety-inducing process of allergen assessment and taste acceptance — every two to three years. Sprout covers the zero-to-three age bracket with its infant formula and toddler drink, while NGS's existing Healthy Heights range targets children aged three and above with clinically supported growth nutrition. Together, the two portfolios cover the entire nutritional journey from birth through to early adolescence without forcing families into a brand switch.

Management has identified cross-selling opportunities that are expected to generate near-term revenue synergies. NGS plans to introduce Sprout's plant-based range into its established U.S. Amazon and Shopify channels, while Healthy Heights products can be pushed into Sprout's existing national pharmacy network and Chinese distribution footprint. Neither move requires significant Capital Expenditure, as both businesses operate what they describe as an asset-light, outsourced Manufacturing model.

Financial Snapshot and Cost Synergies

The combined entity's indicative CY2025 financials reveal a Business that is not yet profitable but is generating meaningful revenue. The combined group recorded unaudited revenues of approximately USD 5.33 million for the calendar year ended 31 December 2025, comprising USD 1.63 million from NGS and USD 3.70 million from Sprout. The consolidated EBITDA loss was approximately USD 1.47 million, while the pre-tax net loss was approximately USD 1.81 million. Management has stressed that these figures do not yet incorporate the identified annualised cost savings of approximately A$870,000, with approximately USD 600,000 of that figure expected to be activated immediately upon completion. The cost savings are expected to flow through shared corporate functions, reduced ASX listing costs, director fee rationalisation, and back-office consolidation.

To fund growth, integration costs, and Working Capital requirements, NGS has also received firm commitments for a Placement of A$2.5 million, raising 125 million new shares at A$0.02 per share. The lead manager for the placement is Taurus Capital Group, which will earn a 6% management fee on gross proceeds, plus up to 25 million Options subject to Shareholder approval. The total post-transaction share count on a fully diluted basis is expected to approach 934.5 million ordinary shares.

Leadership Transition and Governance Changes

The transaction comes with a management refresh. Sprout Founder and CEO Selasi Berdie will assume the role of NGS Chief Executive Officer and Executive Director upon completion. Sprout's Chief Operating Officer, Ben Chester, will become Group COO, while current NGS Executive Director and Interim CEO Manik Pujara will transition to a Non-Executive Director position. The appointment of Mr Berdie as a director remains subject to shareholder approval at the company's upcoming AGM, which is expected to be held approximately six weeks from the announcement date, pointing to a mid-to-late July 2026 meeting. Approximately 90% of consideration shares received by major Sprout shareholders will be subject to 12 months of voluntary Escrow, a structure designed to align the interests of incoming shareholders with the long-term performance of the combined entity.

Looking Ahead: Execution Risk and Next Steps

The completion of the transaction remains contingent on shareholder approval, which means investors should monitor the outcome of the AGM closely. While the strategic rationale is clearly articulated, the combined business still operates at a loss, and successful integration will require careful coordination between two distinct product teams and distribution networks spanning Australia, the United States, and China. The reactivation of previously paused Marketing campaigns, which management notes is now possible following the resolution of inventory issues, will be an important near-term indicator of commercial momentum. The coming months will test whether the asset-light model can scale efficiently across both portfolios without requiring the capital expenditure that typically constrains nutrition businesses at this stage of growth.